Harrow partnerships to support Vevye launch
Click Here to Manage Email Alerts
Key takeaways:
- The Vevye market access program includes PhilRx, Apollo Care and PARx Solutions.
- Harrow expects Vevye to be available next week.
Harrow announced three partnerships to support the upcoming launch of Vevye, indicated for treating the signs and symptoms of dry eye disease.
The partnerships with PhilRx, Apollo Care and PARx Solutions are expected to expand availability of Vevye (cyclosporine ophthalmic solution 0.1%).
PhilRx is a patient access platform that simplifies prior authorizations and streamlines the insurance coverage process for patients, according to a press release. Apollo Care establishes and manages copay program deployment to improve patient access and affordability, while PARx Solutions assists prescribers with issues related to prior authorizations.
“Our 360° approach to market access for Vevye, including these new partnerships with PhilRx, Apollo Care and PARx, is designed to ensure that all patients who can benefit from Vevye and who are prescribed Vevye can get Vevye,” Mark L. Baum, Harrow chairman and CEO, said in the release. “Harrow’s Vevye market access program perfectly aligns with our commitment to providing physicians and their patients with innovative and affordable ophthalmic pharmaceutical products, and the Harrow team eagerly anticipates the availability of Vevye next week.”
Read more about
Click Here to Manage Email Alerts